Cargando…

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer

A significant fraction of advanced prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic castration-resistant prostate cancer (mCRPC)(1). Immune checkpoint blockade (ICB) using antibodies against cytotoxic-T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Xin, Horner, James W., Paul, Erin, Shang, Xiaoying, Troncoso, Patricia, Deng, Pingna, Jiang, Shan, Chang, Qing, Spring, Denise J., Sharma, Padmanee, Zebala, John A., Maeda, Dean Y., Wang, Y. Alan, DePinho, Ronald A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374023/ https://www.ncbi.nlm.nih.gov/pubmed/28321130 http://dx.doi.org/10.1038/nature21676

Ejemplares similares

Effective combinatorial immunotherapy for penile squamous cell carcinoma
por: Huang, Tianhe, et al.
Publicado: (2020)

Genetics and biology of prostate cancer
por: Wang, Guocan, et al.
Publicado: (2018)

Opposing roles of TGFβ and BMP signaling in prostate cancer development
por: Lu, Xin, et al.
Publicado: (2017)

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
por: Gerritsen, Winald R., et al.
Publicado: (2011)

Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy
por: Slovin, Susan R.
Publicado: (2012)

Towards targeted combinatorial therapy design for the treatment of castration-resistant prostate cancer
por: Arshad, Osama Ali, et al.
Publicado: (2017)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy
por: Horn, Lucas A., et al.
Publicado: (2021)

Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer
por: Huber, Marie L., et al.
Publicado: (2012)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies
por: Nahar, Saifun, et al.
Publicado: (2023)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Telomere Dysfunction as an Initiator of Inflammation: Clues to an Age-Old Mystery
por: Chakravarti, Deepavali, et al.
Publicado: (2021)

The Y of cancer sex differences
por: Li, Jiexi, et al.
Publicado: (2023)

Combinatorial Immunotherapies for Metastatic Colorectal Cancer
por: Janssen, Eline, et al.
Publicado: (2020)

Snap-to-it probes: chelate-constrained nucleobase oligomers with enhanced binding specificity
por: Morgan, Joel R., et al.
Publicado: (2008)

Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist
por: Zebala, John A., et al.
Publicado: (2020)

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2012)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
por: Lee, Yu-Ting, et al.
Publicado: (2020)

Targeting YAP-dependent MDSC infiltration impairs tumor progression
por: Wang, Guocan, et al.
Publicado: (2015)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy
por: Liu, Jinping, et al.
Publicado: (2023)

Castration for Hypertrophy of the Prostate Gland
Publicado: (1895)

Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer
por: Shackleton, Erin G., et al.
Publicado: (2021)

Sipuleucel-T: Autologous Cellular Immunotherapy for Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
por: Sims, Robert B.
Publicado: (2011)

A Model-Based Framework to Identify Optimal Administration Protocols for Immunotherapies in Castration-Resistance Prostate Cancer
por: Coletti, Roberta, et al.
Publicado: (2021)

USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation
por: Hou, Pingping, et al.
Publicado: (2019)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
por: Patel, Jesal C., et al.
Publicado: (2013)

Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy
por: Cheng, Heather H., et al.
Publicado: (2015)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

A Case of Castration for Hypertrophied Prostate
Publicado: (1897)

Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer
por: Dudzinski, Stephanie O., et al.
Publicado: (2019)

Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
por: Madan, Ravi A, et al.
Publicado: (2021)

Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer
por: Korentzelos, Dimitrios, et al.
Publicado: (2022)

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study
por: Stein, Mark N, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_otrhgtd3fodr8gf42vmhriq7ho